Losartan Recalled: List of Recalled Sartan Drugs Continues to Grow
On November 9, 2018, the FDA issued a recall of Losartan due to carcinogen contamination concerns. Losartan is now the third “sartan” drug that has been recalled after the carcinogen N-Nitrosodiethylamine (NDEA) was detected in its active pharmaceutical ingredient.
The recalled lots of Losartan were manufactured by Zhejiang Huahai Pharmaceutical Co. Ltd., the same company that manufactured the NDMA-contaminated Valsartan. Since then, the FDA has put Zhejiang Huahai Pharmaceutical on an import alert, meaning the FDA “has enough evidence to allow for Detention Without Physical Examination of products that appear to be in violation of FDA laws and regulations.”
NDEA is a probable human carcinogen and can cause:
- Liver Cancer
- Stomach Cancer
- Colon Cancer
- Intestinal Cancer
- Prostate Cancer (Must be diagnosed before age 60)
- Lower Esophageal Cancer
- Non-Hodgkin Lymphoma
- Multiple Myeloma
- Pancreatic Cancer
If you or a loved one contracted liver cancer, stomach cancer, colorectal cancer, intestinal cancer, esophageal cancer, prostate cancer, pancreatic cancer, non-hodgkin’s lymphoma, leukemia, or multiple myeloma after taking Losartan, contact GoldenbergLaw. Leave the sleepless nights to us.